Developing vaccines and antibody treatments for viral infections.
Official title: Core E: Correlates of Protection
Funded at Washington University · NIH-10863001 · Data updated 2026-11-12
This study is working on developing better vaccines and treatments for serious viruses like dengue and chikungunya, so that people can have safer and more effective ways to prevent and fight these infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 12, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $5,678,163 |
| NIH project number | 1U19AI181960-01 |
| Project ID | NIH-10863001 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children under 12 years old who are at risk for infections caused by flaviviruses and alphaviruses.
✕Less likely to help
Patients who are not at risk for flavivirus or alphavirus infections may not benefit from this research.
What this research studies
This research focuses on creating effective vaccines and antibody therapies for flaviviruses and alphaviruses, which are known to cause severe diseases globally. By utilizing advanced immune assays, the team will evaluate the safety and efficacy of these treatments against various dangerous viruses, including dengue and chikungunya. The research will also analyze existing clinical samples to enhance testing methods and ensure that new vaccines can be rapidly adapted to emerging viral threats. Patients may benefit from improved prevention and treatment options for these viral infections.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines and therapies for patients at risk of severe viral infections.
How similar studies have gone: Previous research has shown promise in developing vaccines and therapies for similar viral infections, indicating a potential for success in this area.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Diamond, Michael S — Washington University
- Study coordinator: Diamond, Michael S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.